LEO Pharma reveals positive top-line Phase III results for tralokinumab

12 December 2019
leo-pharma-big

Danish dermatology specialist LEO Pharma says that tralokinumab – an investigational, fully-human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase III studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo.

IL-13 is a key driver of the type 2 inflammation that plays a major role in AD, which is the most common inflammatory skin disease in the developed world, affecting up to 5% of adults across the USA, Canada, Europe and Japan. AD can have a significant, negative impact on patients’ well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.

LEO Pharma acquired rights for tralokinumab in skin diseases in 2016 from AstraZeneca (LSE: AZN), in a deal that involved and upfront payment of $115 million to the Anglo-Swedish pharma major, as well up to $1 billion in commercially-related milestones and up to mid-teen tiered percentage royalties on product sales. AstraZeneca retains all rights to tralokinumab in respiratory disease and any other indications outside of dermatology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology